Abiopharma

Renalytix is an artificial intelligence enabled in-vitro diagnostics and laboratory services
company that is the global founder and leader in the field of bioprognosis for kidney
health. In late 2023, our kidneyintelX.dkd test was recognized as the first and only
FDA-authorized prognostic test to enable early-stage chronic kidney disease (CKD)
(stages 1-3b) risk assessment for progressive decline in kidney function in type-2 diabetes patients. By understanding how disease will progress, patients and clinicians can
take action earlier to improve outcomes and reduce overall health system costs

Additional info from OTC:
Renalytix is an artificial intelligence enabled in-vitro diagnostics and laboratory services
company that is the global founder and leader in the field of bioprognosis for kidney
health. In late 2023, our kidneyintelX.dkd test was recognized as the first and only
FDA-authorized prognostic test to enable early-stage chronic kidney disease (CKD)
(stages 1-3b) risk assessment for progressive decline in kidney function in type-2 diabetes patients. By understanding how disease will progress, patients and clinicians can
take action earlier to improve outcomes and reduce overall health system costs

Additional info from OTCQB:
Renalytix is an artificial intelligence enabled in-vitro diagnostics and laboratory services
company that is the global founder and leader in the field of bioprognosis for kidney
health. In late 2023, our kidneyintelX.dkd test was recognized as the first and only
FDA-authorized prognostic test to enable early-stage chronic kidney disease (CKD)
(stages 1-3b) risk assessment for progressive decline in kidney function in type-2 diabetes patients. By understanding how disease will progress, patients and clinicians can
take action earlier to improve outcomes and reduce overall health system costs